The management overview indicates that Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, emphasizing operational excellence across its business to position for future growth. The company seeks to transform and simplify care for people with life-threatening illnesses, leveraging its existing portfolio through internal discovery and clinical development programs and product acquisition strategies. The 2017 business highlights reflect strong performance in HIV and cardiovascular products, with a focus on maximizing opportunities in a changing competitive landscape. The company has continued to advance its product pipeline across therapeutic areas, aiming to deliver best-in-class drugs that enhance the current standard of care. The financial highlights reveal a decrease in total revenues and product sales primarily due to competitive dynamics in the HCV market, which has impacted sales of HCV products, while higher sales of HIV products partially offset these declines. Research and development expenses decreased significantly, attributed to prior year impacts of business development activities and ongoing milestone payments, while selling, general and administrative expenses increased due to costs associated with acquisitions and higher branded drug prescription fee expenses. The company emphasizes the importance of mobilizing and deploying IT-based resources in conjunction with leveraging other resources and capabilities to support business strategies and enhance operational efficiency. The strategic management practices focus on resource allocation and investment decisions that align with organizational goals and market dynamics, ensuring that Gilead can respond effectively to competitive actions and external influences. The companyâ€™s IT capabilities are integral to its ability to provide accurate, timely, and reliable information management, which is essential for decision-making and operational flexibility. The management discusses the need for continuous evaluation of R&D activities and the prioritization of efforts based on scientific data and market potential, indicating a commitment to optimizing processes and enhancing firm capabilities. The financial condition reflects a strong cash position and the ability to fund future growth through operational cash flows, while the company remains vigilant regarding market restructuring and competitive positioning. The strategic resource allocation and investment choices are designed to enhance organizational effectiveness and agility, ensuring that Gilead can navigate the complexities of the biopharmaceutical landscape. The focus on innovation partnerships and technology integration is evident in the company's approach to expanding its product pipeline and enhancing its market-based performance. Overall, Gilead's operational strategies and IT governance are aligned with its long-term objectives, emphasizing the critical role of IT capabilities in driving business transformation and achieving competitive advantage in the biopharmaceutical industry.